Comparing Trilostane and Aminoglutethimide for Breast Cancer Treatment
Author Information
Author(s): C.J. Williams, V.L. Barley, G.R. Blackledge, C.G. Rowland, C.J. Tyrrell
Primary Institution: Royal South Hants Hospital, Southampton
Hypothesis
Do Trilostane and Aminoglutethimide confer cross resistance to each other when used to treat postmenopausal advanced breast cancer?
Conclusion
The study suggests that there is no cross resistance between Trilostane and Aminoglutethimide, as both drugs showed similar response rates.
Supporting Evidence
- Objective response rates were 29% for Trilostane and 35% for Aminoglutethimide.
- Four of the 26 patients responded to both therapies.
- Side effects were different between the two drugs, with Trilostane causing more gastrointestinal issues.
Takeaway
This study looked at two medicines for breast cancer and found that they work similarly, so if one doesn't help, the other might.
Methodology
A randomised cross over multicentre comparative study comparing Trilostane and Aminoglutethimide in postmenopausal breast cancer patients.
Potential Biases
Clinicians may have been biased towards continuing Aminoglutethimide treatment despite disease progression.
Limitations
Only 26 of the 72 patients received a second therapy, which may affect the generalizability of the results.
Participant Demographics
Postmenopausal women with advanced breast cancer, average age around 66 years.
Statistical Information
P-Value
<0.01
Confidence Interval
95% confidence limits 15-43% for Trilostane and 19-51% for Aminoglutethimide
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website